LIPO (Lipella Pharmaceuticals) Earnings per share growth rate in current year
Stable raw material supply chains minimize bottleneck risks for Lipella Pharmaceuticals (LIPO). Patent protection within the urological treatment niche guarantees the company sustainable pricing power. Growth potential is based on the transition from costly research to mass production. The annual EPS difference in percentage terms demonstrates the real efficiency of the business, where the 0.00 metric determines this level.
Analytical breakdowns and data insights for company Lipella Pharmaceuticals (LIPO)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital Coefficient Lipella Pharmaceuticals|LIPO - Long-Term Debt to Equity|Current Liabilities to Equity Lipella Pharmaceuticals, Inc.|LIPO - Company Aggregate Debts|Debts to Book Value Lipella Pharmaceuticals, Inc.|LIPO - Company Long-Term Debt|Company Short-Term Debt Lipella Pharmaceuticals|Quick Liquidity lipella.com
- net income and valuation multiples indicators:
LIPO - Net Profit|Projected Future Earnings Lipella Pharmaceuticals|LIPO - Price to Earnings Ratio|Future Price to Earnings Multiple lipella.com|LIPO - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Lipella Pharmaceuticals|LIPO - Operating profit EBITDA|Earnings per share for the trailing year Lipella Pharmaceuticals|LIPO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth lipella.com|LIPO - Earnings per share growth in current year|Expected earnings per share trend next year Lipella Pharmaceuticals
- revenue and sales proceeds data:
Fundamental valuation:LIPO Lipella Pharma
This indicator assesses revenue resilience amid currency volatility, determining real business efficiency through earnings per share dynamics. The formula captures the percentage deviation of current EPS from last year's figures, revealing the growth or degradation rates of capitalization. By analyzing the shift in earnings per share compared to last year, an investor can evaluate the commercialization potential of Lipella Pharmaceuticals (LIPO) targeted therapy within the urological segment.
Main competitors
Earnings per share growth rate in current year Haleon Corp (HLN)|KVUE (Kenvue Inc) - Earnings growth in current year|Earnings per share growth rate in current year veronapharma.com VRNA|Earnings per share growth in current year Jyong Biotech (MENS)|LGND (Ligand Pharmaceuticals Incorporated) - Earnings per share increase in current year|Earnings growth in current year AMRX (Amneal Pharmaceuticals, Inc.)|PRGO (Perrigo Company) - Earnings per share trend in current year|ALVO - Earnings per share growth in current year|Expected net earnings per share growth this year liquidia.com LQDA|Galapagos (GLPG) - Earnings per share growth in current year|ANIP - Expected net earnings per share growth this year|Earnings per share growth in current year MannKind Corporation|AMPH: Earnings per share increase in current year|Earnings per share growth in current year Pacira BioSciences (PCRX)|SPRY: Earnings per share trend in current year|Theravance Biopharma, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year AQST (Aquestive Therapeutics, Inc.)|SCPH - Earnings per share growth in current year|Expected net earnings per share growth this year tectonictx.com TECX|TNXP: Earnings growth in current year|Earnings per share growth this year SXTC|Net earnings per share growth this year EPRX|BioHarvest (BHST) - Expected net earnings per share growth this year|Earnings growth in current year EXOZ|Earnings growth in current year Oramed (ORMP)|Entera Bio Ltd. - Net earnings per share growth this year|ipatherapeutics.com (HYFT) - Earnings per share growth rate in current year|ABVC - Earnings per share growth in current year|Earnings per share trend in current year CPIX|QNTM: Earnings growth in current year|FGEN - Expected net earnings per share growth this year|TELO (Telomir Pharmaceuticals Corp) - Earnings growth in current year|RANI (Rani Therapeutics) - Net earnings per one share growth for the current year|Earnings per share growth in current year Synergy CHC Corp. (SNYR)|RLYB (Rallybio) - Earnings per share increase in current year|Earnings per share growth in current year lexariabioscience.com LEXX|Earnings growth in current year Pulmatrix Corporation PULM|PTHL - Earnings per share growth in current year|Expected net earnings per share growth this year Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Net earnings per share growth this year|IBO - Expected net earnings per share growth this year|Earnings per share growth in current year TNF Pharmaceuticals, Inc.|Net earnings per share growth this year cbdMD, Inc. (YCBD)|Earnings per share growth in current year PainReform Limited (PRFX)|Net earnings per share growth this year Altamira Therapeutics Ltd CYTO|Earnings per share growth in current year OptiNose OPTN|Pieris Pharmaceuticals Inc - Earnings per share growth in current year|Procaps Group Corp - Earnings growth in current year|Expected net earnings per share growth this year Petros Pharma PTPI|Qilian International Holding Group Limited (QLI) - Earnings per share growth in current year|ACELYRIN (SLRN) - Earnings growth in current year|Earnings per share growth in current year TFF Pharmaceuticals
